CD44, a therapeutic target for metastasising tumours

European Journal of Cancer

Volumn 46, Issue 7, 2010, Pages 1271-1277

  Orian Rousseau, Véronique ^a  

^a KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

Author keywords

CD44; Tumours

Indexed keywords

BIVATUZUMAB MERTANSINE; HERMES ANTIGEN; HYALURONIC ACID; MONOCLONAL ANTIBODY; OSTEOPONTIN; PEPTIDE DERIVATIVE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CANCER STAGING; CANCER STEM CELL; CLINICAL TRIAL; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; HEAD AND NECK CARCINOMA; HUMAN; LEUKEMIA CELL; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CHEMOTAXIS; HUMANS; HYALURONIC ACID; LEUKEMIA, MYELOID, ACUTE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; OSTEOPONTIN; PROTEIN ISOFORMS; RATS;

EID: 77950561915     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.024     Document Type: Article

References (49)

1. Ponta H., Sherman L., and Herrlich P.A. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4 1 (2003) 33-45
2. Bennett K.L., Jackson D.G., Simon J.C., et al. CD44 isoforms containing exon v3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 128 (1995) 687-698
3. Jones M., Tussey L., Athanasou N., and Jackson D.G. Heparan sulfate proteoglycan isoforms of the CD44 hyaluronan receptor induced in human inflammatory macrophages can function as paracrine regulators of fibroblast growth factor action. J Biol Chem 275 11 (2000) 7964-7974
4. Kalomiris E.L., and Bourguignon L.Y. Mouse T lymphoma cells contain a transmembrane glycoprotein (GP85) that binds ankyrin. J Cell Biol 106 2 (1988) 319-327
5. Tsukita S., Oishi K., Sato N., Sagara J., and Kawai A. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol 126 2 (1994) 391-401
6. Legg J.W., Lewis C.A., Parsons M., Ng T., and Isacke C.M. A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility. Nat Cell Biol 4 6 (2002) 399-407
7. Günthert U., Hofmann M., Rudy W., et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65 (1991) 13-24
8. Seiter S., Arch R., Reber S., et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 177 2 (1993) 443-455
9. Naor D., Nedvetzki S., Golan I., Melnik L., and Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci 39 6 (2002) 527-579
10. Shtivelman E., and Bishop J.M. Expression of CD44 is repressed in neuroblastoma cells. Mol Cell Biol 11 11 (1991) 5446-5453
11. Gao A.C., Lou W., Dong J.T., and Isaacs J.T. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 57 5 (1997) 846-849
12. De Marzo A.M., Bradshaw C., Sauvageot J., Epstein J.I., and Miller G.J. CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate 34 3 (1998) 162-168
13. Stauder R., Eisterer W., Thaler J., and Günthert U. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood 85 (1995) 2885-2899
14. Wielenga V.J., van der Neut R., Offerhaus G.J., and Pals S.T. CD44 glycoproteins in colorectal cancer: expression, function, and prognostic value. Adv Cancer Res 77 (2000) 169-187
15. Kainz C., Kohlberger P., Tempfer C., et al. Prognostic value of CD44 splice variants in human stage III cervical cancer. Eur J Cancer 31A 10 (1995) 1706-1709
16. Hsieh H.F., Yu J.C., Ho L.I., Chiu S.C., and Harn H.J. Molecular studies into the role of CD44 variants in metastasis in gastric cancer. Mol Pathol 52 1 (1999) 25-28
17. Gotte M., and Yip G.W. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 66 21 (2006) 10233-10237
18. Heider K.H., Kuthan H., Stehle G., and Munzert G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother 53 7 (2004) 567-579
19. Colnot D.R., Wilhelm A.J., Cloos J., et al. Evaluation of limited blood sampling in a preceding 99mTc-labeled diagnostic study to predict the pharmacokinetics and myelotoxicity of 186Re-cMAb U36 radioimmunotherapy. J Nucl Med 42 9 (2001) 1364-1367
20. de Bree R., Roos J.C., Quak J.J., et al. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res 1 6 (1995) 591-598
21. Stroomer J.W., Roos J.C., Sproll M., et al. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin Cancer Res 6 8 (2000) 3046-3055
22. Borjesson P.K., Postema E.J., Roos J.C., et al. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 9 10 Pt 2 (2003) 3961S-3972S
23. Colnot D.R., Roos J.C., De Bree R., et al. Safety, biodistribution, pharmacokinetics, and immunogenicity of (99m)Tc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 52 9 (2003) 576-582
24. Tijink B.M., Buter J., de Bree R., et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 12 20 Pt 1 (2006) 6064-6072
25. Liu C., and Chari R.V. The development of antibody delivery systems to target cancer with highly potent maytansinoids. Expert Opin Investig Drugs 6 2 (1997) 169-172
26. Widdison W.C., Wilhelm S.D., Cavanagh E.E., et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 49 14 (2006) 4392-4408
27. Riechelmann H., Sauter A., Golze W., et al. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 44 9 (2008) 823-829
28. Koppe M., Schaijk F., Roos J., et al. Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer. Cancer Biother Radiopharm 19 6 (2004) 720-729
29. Sleeman J.P., Arming S., Moll J.F., et al. Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells. Cancer Res 56 13 (1996) 3134-3141
30. Yu Q., Toole B.P., and Stamenkovic I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med 186 12 (1997) 1985-1996
31. Yu Q., and Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 13 1 (1999) 35-48
32. Sleeman J., Rudy W., Hofmann M., et al. Regulated clustering of variant CD44 proteins increases their hyaluronate binding capacity. J Cell Biol 135 4 (1996) 1139-1150
33. Kim H.R., Wheeler M.A., Wilson C.M., et al. Hyaluronan facilitates invasion of colon carcinoma cells in vitro via interaction with CD44. Cancer Res 64 13 (2004) 4569-4576
34. Golshani R., Lopez L., Estrella V., et al. Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res 68 2 (2008) 483-491
35. Xu X.M., Chen Y., Chen J., et al. A peptide with three hyaluronan binding motifs inhibits tumor growth and induces apoptosis. Cancer Res 63 18 (2003) 5685-5690
36. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function and association with the malignant process. In: Vande Woude GF, Klein G, editors. Advances in Cancer Research. San-Diego; 1997. p. 243-318.
37. Weber G.F. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552 2 (2001) 61-85
38. Weber G.F., Ashkar S., Glimcher M.J., and Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 271 5248 (1996) 509-512
39. Katagiri Y.U., Sleeman J., Fujii H., et al. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine- glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 59 1 (1999) 219-226
40. Takafuji V., Forgues M., Unsworth E., Goldsmith P., and Wang X.W. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 26 44 (2007) 6361-6371
41. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., and Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12 10 (2006) 1167-1174
42. Legras S., Gunthert U., Stauder R., et al. A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia. Blood 91 9 (1998) 3401-3413
43. Tavor S., Petit I., Porozov S., et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 64 8 (2004) 2817-2824
44. Avigdor A., Goichberg P., Shivtiel S., et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 103 8 (2004) 2981-2989
45. Wainwright DM. Growth factor presentation by CD44 variant proteins. PhD Thesis, Imperial College of Science, Technology and Medicine, London; 1998.
46. Orian-Rousseau V., Chen L., Sleeman J.P., Herrlich P., and Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 16 23 (2002) 3074-3086
47. Orian-Rousseau V., Morrison H., Matzke A., et al. Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell 18 1 (2007) 76-83
48. Matzke A., Herrlich P., Ponta H., and Orian-Rousseau V. A 5-amino-acid peptide blocks Met and Ron dependent cell migration. Cancer Res 65 (2005) 6105-6110
49. Tremmel M., Matzke A., Albrecht I., et al. A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. Blood 114 25 (2009) 5236-5244